Personalis Operating Expenses 2018-2024 | PSNL

Personalis operating expenses from 2018 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Personalis Annual Operating Expenses
(Millions of US $)
2023 $183
2022 $181
2021 $151
2020 $121
2019 $88
2018 $52
2017 $32
Personalis Quarterly Operating Expenses
(Millions of US $)
2024-09-30 $40
2024-06-30 $39
2024-03-31 $38
2023-12-31 $44
2023-09-30 $49
2023-06-30 $42
2023-03-31 $49
2022-12-31 $49
2022-09-30 $42
2022-06-30 $46
2022-03-31 $44
2021-12-31 $41
2021-09-30 $40
2021-06-30 $37
2021-03-31 $33
2020-12-31 $34
2020-09-30 $29
2020-06-30 $29
2020-03-31 $29
2019-12-31 $25
2019-09-30 $23
2019-06-30 $20
2019-03-31 $20
2018-12-31
2018-09-30 $13
2018-06-30 $13
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.261B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00